Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

VRNA

Verona Pharma Plc ADR

Feb 04 • 04:00PM ET

59.94

Dollar change +0.96
Percentage change 1.63	%

Healthcare • Biotechnology • United Kingdom • NASD

Peers: VRTX BIIB REGN AMGN GILD AZN BMY MRNA JNJ PFE

| Held by: IBB SBIO ONEQ AADR GINN BIB IBBQ EUSM FPXE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.94	Insider Own	15.79%	Shs Outstand	81.83M	Perf Week	12.63%
Market Cap	4.90B	Forward P/E	1383.34	EPS next Y	0.04	Insider Trans	-30.62%	Shs Float	68.91M	Perf Month	24.36%
Income	-154.35M	PEG	-	EPS next Q	-0.07	Inst Own	67.31%	Short Float	11.93%	Perf Quarter	76.66%
Sales	5.68M	P/S	863.54	EPS this Y	-177.78%	Inst Trans	2.46%	Short Ratio	6.67	Perf Half Y	185.16%
Book/sh	1.59	P/B	37.59	EPS next Y	117.33%	ROA	-45.78%	Short Interest	8.22M	Perf Year	223.65%
Cash/sh	4.11	P/C	14.60	EPS next 5Y	-	ROE	-78.35%	52W Range	11.39 - 60.81	Perf YTD	29.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	19.36%	ROI	-43.62%	52W High	-1.43%	Beta	0.43
Dividend TTM	-	Quick Ratio	13.03	Sales past 5Y	-49.71%	Gross Margin	72.54%	52W Low	426.25%	ATR (14)	2.80
Dividend Ex-Date	-	Current Ratio	13.03	EPS Y/Y TTM	-197.56%	Oper. Margin	-2746.13%	RSI (14)	73.33	Volatility	5.39% 6.51%
Employees	79	Debt/Eq	1.72	Sales Y/Y TTM	1131.31%	Profit Margin	-2716.65%	Recom	1.00	Target Price	64.22
Option/Short	Yes / Yes	LT Debt/Eq	1.71	EPS Q/Q	-209.13%	Payout	-	Rel Volume	1.00	Prev Close	58.98
Sales Surprise	177.81%	EPS Surprise	-2.94%	Sales Q/Q	-	Earnings	Nov 04 BMO	Avg Volume	1.23M	Price	59.94
SMA20	14.26%	SMA50	30.23%	SMA200	105.64%	Trades		Volume	1,231,353	Change	1.63%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-10-25	Initiated	ROTH MKM	Buy	$68
Oct-03-24	Initiated	Wells Fargo	Overweight	$50
May-22-23	Resumed	Jefferies	Buy	$35 → $38
Sep-19-22	Resumed	Wedbush	Outperform	$27
Aug-26-22	Initiated	Piper Sandler	Overweight	$31
Sep-13-21	Initiated	H.C. Wainwright	Buy	$25
Aug-25-20	Initiated	Jefferies	Buy	$17
Aug-10-20	Initiated	Canaccord Genuity	Buy	$17
Apr-18-19	Initiated	BTIG Research	Buy	$17

Jan-27-25 08:50AM	Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA) (Zacks)
Jan-20-25 03:11PM	Is Verona Pharma (VRNA) Among Billionaire Joseph Edelmans Long-Term Stock Picks? (Insider Monkey)
Jan-16-25 04:04PM	Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This Week (Investor's Business Daily) +6.62%
Jan-14-25 09:55AM	Wall Street Analysts See a 30.65% Upside in Verona Pharma (VRNA): Can the Stock Really Move This High? (Zacks)
Jan-10-25 12:00PM	Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
08:50AM	Loading…
08:50AM	Verona Pharma (VRNA) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jan-07-25 06:00AM	Verona Pharma Reports Strong Ohtuvayre Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights (GlobeNewswire) +10.58%
Nov-19-24 02:00AM	Verona Pharma Announces December 2024 Investor Conference Participation (GlobeNewswire) +9.02%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-05-24 02:03AM	Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs (GuruFocus.com)
02:00AM	Verona Pharma to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-24 02:00AM	Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +9.06%
Nov-01-24 09:03AM	Verona Pharma PLC (VRNA) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-25-24 08:50AM	Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why (Zacks)
Oct-21-24 02:00AM	Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
09:55AM	Loading…
Oct-11-24 09:55AM	Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet (Zacks)
Oct-09-24 08:50AM	Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Sep-30-24 02:00AM	Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024 (GlobeNewswire)
Sep-17-24 08:29AM	Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)* (PR Newswire)
Sep-14-24 01:52AM	Insider Sale: CFO Mark Hahn Sells 600,000 Shares of Verona Pharma PLC (VRNA) (GuruFocus.com)
01:51AM	Verona Pharma PLC (VRNA) CEO David Zaccardelli Sells 600,000 Shares (GuruFocus.com)
Sep-05-24 02:00AM	Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024 (GlobeNewswire)
Aug-15-24 12:02AM	Insider Sale: CFO Mark Hahn Sells 400,000 Shares of Verona Pharma PLC (VRNA) (GuruFocus.com)
Aug-09-24 07:33AM	Is Verona Pharma plc (VRNA) a Good Addition to Your Portfolio Now? (Insider Monkey)
Aug-08-24 02:00AM	Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +10.60%
Jul-30-24 02:00AM	Verona Pharma to Present at 44th Annual Canaccord Growth Conference (GlobeNewswire)
Jul-25-24 02:00AM	Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire) +5.13%
Jul-12-24 11:08AM	Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why (Zacks)
Jun-27-24 12:22PM	Verona scores FDA approval for Ohtuvayre as COPD maintenance therapy (Pharmaceutical Technology) +5.11%
09:49AM	First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product (Benzinga)
09:00AM	Loading…
09:00AM	FDA approves Verona Pharma's Ohtuvayre for COPD treatment (Pharmaceutical Business Review)
08:42AM	FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market (Pharmaceutical Technology)
Jun-26-24 04:57PM	Verona Pharma Announces US FDA Approval of Ohtuvayre (ensifentrine) (GlobeNewswire)
Jun-13-24 08:00AM	Why It's A New Day For COPD Patients And Regeneron, Sanofi, Verona Stocks (Investor's Business Daily) +5.49%
May-29-24 08:46AM	Verona prepares for anticipated US launch of ensifentrine for COPD in Q3 2024 (Pharmaceutical Technology)
May-10-24 01:57PM	Verona Pharma PLC Reports Q1 2024 Earnings: A Detailed Financial and Strategic Overview (GuruFocus.com)
12:06PM	Verona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 11:38AM	Verona Pharma Signs Financing Agreements for Up to $650 Million (MT Newswires)
11:04AM	Verona Pharma Shares Decline After Q1 Loss Widens (MT Newswires)
07:15AM	Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS (GlobeNewswire)
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 02:00AM	Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 (GlobeNewswire)
Apr-25-24 02:00AM	Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Mar-04-24 02:00AM	Andrew Fisher Joins Verona Pharma as General Counsel (GlobeNewswire) -5.00%
Mar-01-24 09:03AM	Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.63%
08:45AM	3 Healthcare Stocks That Have Outperformed Nvidia Since 2022 (Motley Fool)
Feb-29-24 06:36AM	Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
02:00AM	Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-15-24 02:00AM	Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Feb-01-24 02:00AM	Michael Austwick Joins Verona Pharma as Non-Executive Director (GlobeNewswire)
Jan-03-24 02:00AM	Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-24 02:00AM	Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital (GlobeNewswire) -5.38%
Dec-30-23 06:50AM	3 Stocks That Could Be Monster Winners in 2024 (Motley Fool)
Nov-23-23 09:55AM	Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to Trade (Zacks)
Nov-17-23 02:00AM	Verona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award (GlobeNewswire) +6.28%
Nov-14-23 09:09AM	11 Best Undervalued UK Stocks To Buy Now (Insider Monkey) +5.62%
Nov-08-23 02:00AM	Verona Pharma Announces November 2023 Investor Conference Participation (GlobeNewswire)
Nov-07-23 09:55AM	Does Verona Pharma PLC American Depositary Share (VRNA) Have the Potential to Rally 119.18% as Wall Street Analysts Expect? (Zacks)
Nov-05-23 10:33AM	Verona Pharma plc (NASDAQ:VRNA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-04-23 05:02AM	Insider Sell: Chief Medical Officer Kathleen Rickard Sells 58,752 Shares of Verona Pharma PLC (GuruFocus.com)
Nov-02-23 08:03AM	Verona Pharma PLC (VRNA) Reports Q3 2023 Financial Results and Corporate Update (GuruFocus.com)
03:04AM	Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-23-23 04:57AM	Analysts Say These 3 Stocks Are Their Top Picks for 2024 (TipRanks)
Oct-19-23 02:00AM	Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-11-23 09:55AM	Verona Pharma PLC American Depositary Share (VRNA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Oct-06-23 02:00AM	Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023 (GlobeNewswire)
Oct-04-23 09:35AM	Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround (Zacks)
Oct-03-23 02:00AM	Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023 (GlobeNewswire)
Sep-26-23 12:17PM	Raleigh pharma preps for hiring spree, expands office footprint with sublease (American City Business Journals)
Sep-11-23 02:00AM	Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD (GlobeNewswire)
Sep-06-23 02:00AM	Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023 (GlobeNewswire)
Aug-31-23 10:16PM	12 Best High Risk High Reward Stocks To Buy Now (Insider Monkey) +5.03%
02:00AM	Christina Ackermann Joins Verona Pharma as Non-Executive Director (GlobeNewswire)
Aug-08-23 07:42AM	Verona Pharma plc's (NASDAQ:VRNA) institutional investors lost 14% over the past week but have profited from longer-term gains (Simply Wall St.)
06:41AM	Verona Pharma plc (NASDAQ:VRNA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 02:00AM	Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-26-23 02:00AM	Verona Pharma to Present at 43rd Annual Canaccord Growth Conference (GlobeNewswire)
Jul-20-23 02:00AM	Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jun-28-23 02:00AM	Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine (GlobeNewswire)
Jun-27-23 02:00AM	Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD (GlobeNewswire)
May-24-23 02:00AM	Verona Pharma to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-09-23 02:00AM	Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-23 02:00AM	Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023 (GlobeNewswire)
Apr-25-23 02:00AM	Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Apr-11-23 06:05AM	When Will Verona Pharma plc (NASDAQ:VRNA) Breakeven? (Simply Wall St.)
Apr-10-23 02:00AM	Nuance Pharma Announces Dosing of First Patient in ENHANCE China Phase 3 Trial for COPD (GlobeNewswire)
Apr-04-23 06:15PM	Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know (Zacks)
Mar-30-23 05:22PM	Top Healthcare Stocks for April 2023 (Investopedia)
Mar-28-23 06:15PM	Verona Pharma PLC American Depositary Share (VRNA) Dips More Than Broader Markets: What You Should Know (Zacks)
Mar-22-23 06:00PM	Verona Pharma PLC American Depositary Share (VRNA) Stock Moves -0.46%: What You Should Know (Zacks)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-14-23 06:15PM	Verona Pharma PLC American Depositary Share (VRNA) Stock Sinks As Market Gains: What You Should Know (Zacks)
Mar-09-23 01:59AM	Verona Pharma plc (NASDAQ:VRNA) Q4 2022 Earnings Call Transcript (Insider Monkey) -9.20%
Mar-08-23 02:50PM	Top Healthcare Stocks for March 2023 (Investopedia)
07:56AM	Raleigh drugmaker eyes regulatory push for COPD treatment (American City Business Journals)
Mar-07-23 02:00AM	Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -10.51%
Mar-01-23 06:00PM	Verona Pharma PLC American Depositary Share (VRNA) Gains As Market Dips: What You Should Know (Zacks)
05:57AM	Verona Pharma plc (NASDAQ:VRNA) is definitely on the radar of institutional investors who own 39% of the company (Simply Wall St.)
Feb-23-23 06:00PM	Verona Pharma PLC American Depositary Share (VRNA) Gains But Lags Market: What You Should Know (Zacks)

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ZACCARDELLI DAVID	President and CEO	Dec 05 '24	Sale	5.01	640,264	3,205,226	14,367,552	Dec 06 05:51 PM
ZACCARDELLI DAVID	President and CEO	Dec 06 '24	Sale	5.01	162,800	815,400	14,204,752	Dec 06 05:51 PM
ZACCARDELLI DAVID	President and CEO	Dec 04 '24	Sale	5.00	67,608	338,162	15,007,816	Dec 06 05:51 PM
Hahn Mark W	Chief Financial Officer	Dec 05 '24	Sale	5.01	640,048	3,204,144	13,477,464	Dec 06 05:50 PM
Hahn Mark W	Chief Financial Officer	Dec 06 '24	Sale	5.01	183,728	920,312	13,293,736	Dec 06 05:50 PM
Hahn Mark W	Chief Financial Officer	Dec 04 '24	Sale	5.00	58,184	290,996	14,117,512	Dec 06 05:50 PM
Hahn Mark W	Chief Financial Officer	Nov 29 '24	Sale	5.01	98,704	494,142	14,177,296	Dec 02 07:20 PM
Hahn Mark W	Chief Financial Officer	Nov 27 '24	Sale	5.00	12,936	64,680	14,276,000	Dec 02 07:20 PM
Hahn Mark W	Chief Financial Officer	Dec 02 '24	Sale	5.00	1,600	8,000	14,175,696	Dec 02 07:20 PM
ZACCARDELLI DAVID	President and CEO	Nov 29 '24	Sale	5.01	98,888	495,033	15,078,624	Dec 02 07:19 PM
ZACCARDELLI DAVID	President and CEO	Nov 27 '24	Sale	5.00	23,240	116,200	15,177,512	Dec 02 07:19 PM
ZACCARDELLI DAVID	President and CEO	Dec 02 '24	Sale	5.00	3,200	16,000	15,075,424	Dec 02 07:19 PM
Hahn Mark W	Chief Financial Officer	Nov 25 '24	Sale	5.00	1,600	8,000	14,289,736	Nov 26 06:36 PM
Hahn Mark W	Chief Financial Officer	Nov 26 '24	Sale	5.00	800	4,000	14,288,936	Nov 26 06:36 PM
ZACCARDELLI DAVID	President and CEO	Nov 25 '24	Sale	5.00	1,600	8,000	15,200,752	Nov 26 06:35 PM
Rickard Kathleen A.	Chief Medical Officer	Nov 25 '24	Sale	4.90	240,000	1,176,360	2,671,480	Nov 26 06:34 PM
KATHLEEN A RICKARD	Officer	Nov 25 '24	Proposed Sale	39.21	30,000	1,176,357		Nov 25 04:42 PM
EBSWORTH DAVID R	Director	Nov 18 '24	Buy	4.44	20,000	88,800	940,003	Nov 18 04:20 PM
ZACCARDELLI DAVID	President and CEO	Nov 11 '24	Sale	5.00	2,400	12,000	15,202,352	Nov 13 04:58 PM
Hahn Mark W	Chief Financial Officer	Nov 11 '24	Sale	5.00	2,400	12,000	14,291,336	Nov 13 04:57 PM
MARK HAHN	Officer	Nov 11 '24	Proposed Sale	38.58	125,000	4,822,500		Nov 12 07:55 AM
EBSWORTH DAVID R	Director	Nov 06 '24	Buy	4.80	39,360	188,881	920,003	Nov 07 06:57 PM
ACKERMANN CHRISTINA	Director	Nov 06 '24	Buy	4.74	41,880	198,386	41,880	Nov 07 06:56 PM
ZACCARDELLI DAVID	President and CEO	Nov 04 '24	Sale	4.39	94,144	413,462	15,204,752	Nov 05 05:41 PM
ZACCARDELLI DAVID	President and CEO	Nov 01 '24	Sale	4.38	46,888	205,196	15,298,896	Nov 05 05:41 PM
Hahn Mark W	Chief Financial Officer	Nov 04 '24	Sale	4.39	80,784	354,448	14,293,736	Nov 05 05:40 PM
Hahn Mark W	Chief Financial Officer	Nov 01 '24	Sale	4.38	48,888	213,939	14,374,520	Nov 05 05:40 PM
Hahn Mark W	Chief Financial Officer	Oct 24 '24	Sale	4.38	141,360	618,761	13,672,560	Oct 25 07:55 PM
Hahn Mark W	Chief Financial Officer	Oct 25 '24	Sale	4.38	3,200	14,000	13,669,360	Oct 25 07:55 PM
ZACCARDELLI DAVID	President and CEO	Oct 24 '24	Sale	4.38	140,000	612,822	14,596,536	Oct 25 07:54 PM
ZACCARDELLI DAVID	President and CEO	Oct 25 '24	Sale	4.38	4,800	21,004	14,591,736	Oct 25 07:54 PM
ZACCARDELLI DAVID	President and CEO	Oct 23 '24	Sale	4.38	16	70	14,736,536	Oct 25 07:54 PM
ZACCARDELLI DAVID	President and CEO	Oct 18 '24	Sale	4.38	245,784	1,076,755	15,004,920	Oct 22 08:46 PM
ZACCARDELLI DAVID	President and CEO	Oct 22 '24	Sale	4.39	157,912	692,728	14,736,552	Oct 22 08:46 PM
ZACCARDELLI DAVID	President and CEO	Oct 21 '24	Sale	4.38	110,456	483,753	14,894,464	Oct 22 08:46 PM
Hahn Mark W	Chief Financial Officer	Oct 18 '24	Sale	4.38	249,728	1,093,983	14,089,960	Oct 22 08:45 PM
Hahn Mark W	Chief Financial Officer	Oct 22 '24	Sale	4.38	159,344	698,708	13,813,920	Oct 22 08:45 PM
Hahn Mark W	Chief Financial Officer	Oct 21 '24	Sale	4.38	116,696	511,082	13,973,264	Oct 22 08:45 PM
MARK HAHN	Officer	Oct 18 '24	Proposed Sale	34.66	100,000	3,466,000		Oct 18 04:20 PM
DAVID ZACCARDELLI	Director	Oct 18 '24	Proposed Sale	34.66	100,000	3,466,000		Oct 18 04:20 PM
ZACCARDELLI DAVID	President and CEO	Sep 11 '24	Sale	3.76	600,000	2,254,320	15,250,704	Sep 13 04:15 PM
Hahn Mark W	Chief Financial Officer	Sep 11 '24	Sale	3.76	600,000	2,254,080	14,339,688	Sep 13 04:15 PM
MARK HAHN	Officer	Sep 11 '24	Proposed Sale	28.04	75,000	2,103,000		Sep 11 04:22 PM
DAVID ZACCARDELLI	Director	Sep 11 '24	Proposed Sale	28.04	75,000	2,103,000		Sep 11 04:22 PM
ZACCARDELLI DAVID	President and CEO	Aug 13 '24	Sale	3.20	398,400	1,275,681	15,850,704	Aug 14 04:16 PM
ZACCARDELLI DAVID	President and CEO	Aug 12 '24	Sale	3.13	1,600	5,008	16,249,104	Aug 14 04:16 PM
Hahn Mark W	Chief Financial Officer	Aug 13 '24	Sale	3.20	398,400	1,275,540	14,939,688	Aug 14 04:15 PM
Hahn Mark W	Chief Financial Officer	Aug 12 '24	Sale	3.13	1,600	5,008	15,338,088	Aug 14 04:15 PM
EBSWORTH DAVID R	Director	Aug 12 '24	Buy	2.87	36,000	103,320	880,643	Aug 14 04:15 PM
DAVID ZACCARDELLI	Officer	Aug 12 '24	Proposed Sale	22.62	50,000	1,131,000		Aug 12 04:20 PM
MARK HAHN	Officer	Aug 12 '24	Proposed Sale	22.62	50,000	1,131,000		Aug 12 04:20 PM
Rickard Kathleen A.	Chief Medical Officer	May 03 '24	Sale	1.96	36,248	71,032	2,621,552	May 03 07:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRNA

Verona Pharma Plc ADR

Upgrade your FINVIZ experience